Literature DB >> 10664504

Nitric oxide prevents p21 degradation with the ubiquitin-proteasome pathway in vascular smooth muscle cells.

M R Kibbe1, S Nie, D W Seol, I Kovesdi, A Lizonova, M Makaroun, T R Billiar, E Tzeng.   

Abstract

PURPOSE: We have shown that gene transfer of the inducible nitric oxide synthase (iNOS) gene to injured arteries inhibits the development of intimal hyperplasia. One mechanism by which nitric oxide (NO) may inhibit this process is through the upregulation of the cyclin-dependent kinase inhibitor p21, which induces a G0/G1 cell cycle arrest, leading to an inhibition of vascular smooth muscle cell (VSMC) proliferation. Because NO induced such a dramatic upregulation of p21 and because p21 is a universal inhibitor of the cell cycle, this study aimed to determine how NO upregulates p21 protein expression in VSMCs.
METHODS: p21 messenger RNA (mRNA) levels in rat aortic smooth muscle cells (RASMCs) were determined by Northern blot analysis after treatment with S-nitroso-N-acetylpenicillamine (SNAP) or after adenoviral iNOS gene transfer. p21 protein levels in RASMCs in similar conditions were determined by Western blot analysis. Levels of ubiquinated p21 in these same treatment groups were assessed by immunoprecipitation of p21 from RASMCs, followed by western blot analysis for ubiquitin. Protein tyrosine and protein serine/threonine phosphatase activity after treatment with SNAP, plus or minus the phosphatase inhibitors calyculin A or cantharidin, were measured with (32)P-labeled myelin basic protein as a substrate.
RESULTS: NO exposure by the NO-donor SNAP or iNOS gene transfer induced a dose- and time-dependent increase in p21 protein expression in RASMCs. p21 mRNA levels were significantly increased after SNAP treatment only at the 6-hour point, but were not increased at 24 hours. In contrast, protein levels were increased from 6 to 24 hours, and transcriptional inhibitors did not inhibit this increase in protein synthesis. The increase in p21 protein expression induced by NO was associated with less of the ubiquinated form of p21 at both early and late points. Furthermore, NO induced an increase in both protein tyrosine and protein serine/threonine phosphatase activity. Inhibition of these phosphatases with calyculin A or cantharidin prevented the upregulation of p21 protein expression by NO.
CONCLUSION: These data indicate that one mechanism by which NO upregulates p21 protein expression is through the prevention of p21 protein degradation by the ubiquitin-proteasome pathway in association with increased protein tyrosine and serine/threonine phosphatase activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10664504     DOI: 10.1016/s0741-5214(00)90166-6

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  10 in total

1.  Insights into the effect of nitric oxide and its metabolites nitrite and nitrate at inhibiting neointimal hyperplasia.

Authors:  Ashley K Vavra; George E Havelka; Janet Martinez; Vanessa R Lee; Bo Fu; Qun Jiang; Larry K Keefer; Melina R Kibbe
Journal:  Nitric Oxide       Date:  2011-04-30       Impact factor: 4.427

2.  Nitric oxide increases lysine 48-linked ubiquitination following arterial injury.

Authors:  Chris S Oustwani; Nick D Tsihlis; Ashley K Vavra; Qun Jiang; Janet Martinez; Melina R Kibbe
Journal:  J Surg Res       Date:  2011-06-15       Impact factor: 2.192

3.  Nitric oxide inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia by increasing the ubiquitination and degradation of UbcH10.

Authors:  Nick D Tsihlis; Chris S Oustwani; Ashley K Vavra; Qun Jiang; Larry K Keefer; Melina R Kibbe
Journal:  Cell Biochem Biophys       Date:  2011-06       Impact factor: 2.194

4.  Isopropylamine NONOate (IPA/NO) moderates neointimal hyperplasia following vascular injury.

Authors:  Nick D Tsihlis; Jozef Murar; Muneera R Kapadia; Sadaf S Ahanchi; Christopher S Oustwani; Joseph E Saavedra; Larry K Keefer; Melina R Kibbe
Journal:  J Vasc Surg       Date:  2010-03-11       Impact factor: 4.268

5.  Nitric oxide affects UbcH10 levels differently in type 1 and type 2 diabetic rats.

Authors:  Monica P Rodriguez; Nick D Tsihlis; Zachary M Emond; Zheng Wang; Vinit N Varu; Qun Jiang; Janet M Vercammen; Melina R Kibbe
Journal:  J Surg Res       Date:  2015-02-13       Impact factor: 2.192

6.  Nitric oxide inhibits neointimal hyperplasia following vascular injury via differential, cell-specific modulation of SOD-1 in the arterial wall.

Authors:  Edward S M Bahnson; Nathaniel Koo; Nadiezhda Cantu-Medellin; Aaron Y Tsui; George E Havelka; Janet M Vercammen; Qun Jiang; Eric E Kelley; Melina R Kibbe
Journal:  Nitric Oxide       Date:  2014-11-07       Impact factor: 4.427

7.  Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome.

Authors:  Sadaf S Ahanchi; Vinit N Varu; Nick D Tsihlis; Janet Martinez; Charles G Pearce; Muneera R Kapadia; Qun Jiang; Joseph E Saavedra; Larry K Keefer; Joseph A Hrabie; Melina R Kibbe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-10-17       Impact factor: 4.733

8.  Identification of nitric oxide as an endogenous inhibitor of 26S proteasomes in vascular endothelial cells.

Authors:  Hongtao Liu; Shujie Yu; Hua Zhang; Jian Xu
Journal:  PLoS One       Date:  2014-05-22       Impact factor: 3.240

9.  S-nitrosylation-dependent proteasomal degradation restrains Cdk5 activity to regulate hippocampal synaptic strength.

Authors:  Peng Zhang; Wing-Yu Fu; Amy K Y Fu; Nancy Y Ip
Journal:  Nat Commun       Date:  2015-10-27       Impact factor: 14.919

10.  p63α modulates c-Myc activity via direct interaction and regulation of MM1 protein stability.

Authors:  Anning Han; Juan Li; Yimin Li; Yang Wang; Johann Bergholz; Yujun Zhang; Chenghua Li; Zhi-Xiong Xiao
Journal:  Oncotarget       Date:  2016-07-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.